Quarterly report pursuant to Section 13 or 15(d)

Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited)

v3.8.0.1
Consolidated Condensed Interim Statement of Loss and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Expenses        
Research and development $ 2,141,945 $ 1,120,910 $ 4,076,588 $ 1,853,639
General and administrative 1,011,879 571,286 1,756,500 1,887,925
Operating Expenses 3,153,824 1,692,196 5,833,088 3,741,564
Other loss (income)        
Change in fair value of stock option and derivative liabilities 889 (361,668) (55,679) (135,980)
Foreign exchange loss (gain) 7,120 (8,495) 50,986 6,829
Interest income (235) (60) (391) (101)
Other (income) loss 7,774 (370,223) (5,084) (129,252)
Net and comprehensive loss for the period 3,161,598 1,321,973 5,828,004 3,612,312
Computation of basic loss per share        
Net and comprehensive loss for the period 3,161,598 1,321,973 5,828,004 3,612,312
Series B Preferred stock dividend 54,066 159,756 95,732 467,054
Net and comprehensive loss available to common stockholders $ 3,215,664 $ 1,481,729 $ 5,923,736 $ 4,079,366
Basic and fully diluted loss per share $ 0.14 $ 0.13 $ 0.31 $ 0.36
Basic weighted average number of shares 22,559,234 11,424,485 18,882,259 11,363,237